Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Dasatinib+letrozole improves survival for women with hormone receptor-positive, HER2-negative metastatic breast cancer

Advanced genetics technologies may help predict patient outcomes in people with ALL

Advanced genetics technologies may help predict patient outcomes in people with ALL

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

Nano-biosensors along with new  imaging techniques can improve drug targeting in pancreatic cancer

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

European Commission grants conditional marketing authorization for Pfizer's BOSULIF

European Commission grants conditional marketing authorization for Pfizer's BOSULIF

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Memorial Sloan-Kettering scientist wins Breakthrough Prize in Life Sciences

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

FDA approves Bosulif to treat chronic myelogenous leukemia

FDA approves Bosulif to treat chronic myelogenous leukemia

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

Scientists identify new genetic alterations underlying high-risk subtype of ALL

Scientists identify new genetic alterations underlying high-risk subtype of ALL

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML